NDLI: Rituximab in the treatment of rheumatoid arthritis.

Please wait, while we are loading the content...

Year: 2017 Volume: 13

Year: 2016 Volume: 12

Year: 2015 Volume: 11

Year: 2014 Volume: 10

Year: 2013 Volume: 9

Year: 2012 Volume: 8

Year: 2011 Volume: 7

Year: 2010 Volume: 6

Year: 2009 Volume: 5

Year: 2008 Volume: 4

Year: 2007 Volume: 3

Year: 2007 Volume: 3 Issue: 6

Year: 2007 Volume: 3 Issue: 5

Year: 2007 Volume: 3 Issue: 4

Year: 2007 Volume: 3 Issue: 3

Year: 2007 Volume: 3 Issue: 2

Year: 2007 Volume: 3 Issue: 1

Complement in host defense and tissue injury: from basic biology to translational research.

The emerging field of glycoimmunology: highlights from the Society for Glycobiology meeting, 2006.

Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy.

Rituximab in the treatment of rheumatoid arthritis.

Methotrexate in rheumatoid arthritis.

Paradoxical roles of interferon-gamma in autoimmune disease.

The metabolic syndrome and adipocytokines.

Occupational asthma: what can be done to prevent it?

T-cell response dynamics in animal models of multiple sclerosis: implications for immunotherapies.

B-cell subsets: cellular interactions and relevance in multiple sclerosis.

Role of fine needle aspiration cytology in thyroiditis.

Year: 2006 Volume: 2

Year: 2005 Volume: 1

Rituximab in the treatment of rheumatoid arthritis.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Taylor, Peter C.
Description	Country affiliation: United kingdom Author Affiliation: Taylor PC ( The Kennedy Institute Division, Imperial College School of Medicine, 1 Aspenlea Road London, W6 8LH, UK. peter.c.taylor@imperial.ac.uk)
Abstract	Rheumatoid arthritis is a chronic, disabling condition and the most common form of inflammatory arthritis affecting approximately 1% of the population. The outlook has improved considerably over the last decade with the recognition that better outcomes accompany early and optimal suppression of synovitis. In some patients, this can be achieved with conventional, oral disease-modifying anti-rheumatic drugs. For those with more severe disease, the introduction of biologic therapies targeting the pro-inflammatory cytokine tumor necrosis factor (TNF)-alpha has led to further, significant improvements in outcome. However, in general, these drugs are being used for long-term maintenance therapy and are associated with a very high expense that limits their availability in most healthcare economies. Furthermore, approximately a third of patients fail to achieve clinically significant responses. There is therefore a need for new, effective approaches to therapy, in particular for those patients refractory to TNF blockade. Rituximab, a B cell-depleting antibody, is the first biologic targeting B cells to be approved in the USA and Europe for the treatment of active rheumatoid arthritis in anti-TNF non-responders. This article reviews the background to this therapeutic approach and the encouraging clinical trial data to date indicating that enduring responses can be achieved in a majority of patients after a single treatment cycle comprising two rituximab infusions given 2 weeks apart.
File Format	HTM / HTML
ISSN	1744666X
Issue Number	1
Journal	Expert Review of Clinical Immunology
Volume Number	3
e-ISSN	17448409
Language	English
Publisher	Taylor & Francis
Publisher Date	2007-01-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Immunology
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in